Dr. Rob Schott Joins Nutcracker Therapeutics as Chief Medical Officer
September 12, 2022
Dr. Schott will oversee the advancement of Nutcracker Therapeutics’ oncology pipeline, helping to expand the company’s novel RNA therapeutics platform The announcement follows several recent C-suite hires, adding significant pharmaceutical industry and drug development experience to Nutcracker Therapeutics’ executive team EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies […]
Nutcracker Therapeutics Bolsters Leadership with Chief Operating Officer and Other Key Hires, Reveals Oncology Pipeline
June 22, 2022
John Stubenrauch, Ph.D., joins as Chief Operating Officer The company also appointed Geoff Nosrati, Ph. D., as Chief Business Officer and Ian Wiener, J.D., as General Counsel Nutcracker Therapeutics reveals oncology-focused pipeline programs, with lead candidate in IND-enabling studies EMERYVILLE, Calif. — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through […]
Emeryville, Calif. – March 14, 2022 Financing round led by returning investor ARCH Venture Partners Enables accelerated development of therapeutic pipeline built upon its proprietary RNA technology platform Industry veteran Michael F. Bigham appointed to the board of directors Nutcracker Therapeutics, Inc., a biotech company developing RNA therapeutics using its proprietary biochip-based manufacturing platform, today […]
Nutcracker Therapeutics Announces $60 Million Series B Financing to Advance mRNA Therapeutics Produced on Transformational Biochip-based ACORN Platform
September 23, 2020
Emeryville, Calif. – September 23, 2020 Financing led by ARCH Venture Partners Company aims to efficiently develop, manufacture and deliver mRNA medicines to patients worldwide using its proprietary push-button “GMP-in-a-box” system Company will initially focus on developing first-in-class mRNA therapeutics for oncology indications and forging collaborations with biotech and pharma companies Nutcracker Therapeutics, Inc., a […]
Nutcracker Therapeutics Strengthens Leadership Team with Appointment of Madhavan Balachandran as Chief Operating Officer
September 23, 2020
Emeryville, Calif. – September 23, 2020 – Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced the appointment of Madhavan (“Madhu”) Balachandran, former executive vice president of operations at Amgen, as chief operating officer. Mr. Balachandran will oversee all operational aspects of the company including manufacturing […]
For inquiries, please visit our Contact Page.
